Cold Spring Harbor Laboratory Study Finds Cancer Fighting Antibodies Linked to Severe Autoimmune Brain Disorders

Cold Spring Harbor Laboratory researchers find that antibodies shrinking tumors can also trigger severe brain inflammation and autoimmune conditions.

By: AXL Media

Published: Mar 26, 2026, 10:15 AM EDT

Source: Information for this report was sourced from Cold Spring Harbor Laboratory

The Link Between Hidden Tumors and Autoimmunity

A groundbreaking study from Cold Spring Harbor Laboratory has proposed a solution to two long-standing medical mysteries regarding how the body manages mutated cells and why autoimmune conditions appear suddenly. According to the research published in Nature, the human immune system possesses pre-equipped antibodies capable of attacking tumors, yet these same molecules can mistakenly target the brain. Lead researcher Sam Kleeman suggests that many patients who experience a sudden onset of autoimmune disease may actually be reacting to a cancer they were never aware existed within their bodies.

The Neurological Impact of Anti-Tumor Responses

The investigation specifically examined anti-NMDA receptor encephalitis, a condition where the immune system attacks vital brain proteins, leading to seizures, psychosis, and insomnia. Many patients suffering from this neurological disorder are found to have tumors that produce the same NMDA receptors typically found in the brain. By using mouse models of breast cancer, the scientific team traced how antibodies present at birth evolve within a tumor to become potent cancer-killing agents. While these evolved molecules successfully caused tumors to shrink, they simultaneously induced severe neurological symptoms when introduced to healthy brain tissue.

Opposing Effects of Shared Antibody Pathways

A significant breakthrough in the study occurred when Professor Hiro Furukawa utilized cryo-electron microscopy to analyze the molecular structure of these antibodies. The analysis revealed that a single immune response against a tumor could produce antibodies with diametrically opposed effects, some activating receptors while others inhibited them. According to Furukawa, identifying the difference between these harmful and protective molecules is essential for developing future treatments. The goal is to create therapies that maintain the body’s ability to fight cancer without causing collateral damage to the nervous system.